Diagnostic accuracy and pitfalls of [iodine-131]6-beta-iodomethyl-19-norcholesterol (NP-59) imaging.

Published

Journal Article

NP-59 concentrates in steroid hormone synthesizing tissues, enabling scintigraphic localization and characterization of endocrine dysfunction in the adrenal cortex and ovary. Studying 108 consecutive cases from 1982 to 1985 and using clinical, biochemical, radiographic, and pathologic data, we performed a rigorous assessment of the accuracy and pitfalls of NP-59 scintigraphy. The evaluation was divided into categories of abnormal hormone secretion: Cushing's syndrome, primary aldosteronism, and hyperandrogenism. Additional categories included euadrenal tumors (without detectable hormone dysfunction) and sites of residual adrenal cortical tissue. The accuracy of NP-59 scintigraphy ranged from 71% in primary aldosteronism and 75% in euadrenal tumors, to 100% for Cushing's syndrome and hyperandrogenism. However, more than in most nuclear medicine studies, NP-59 imaging requires well-defined indications to be met for it to be efficacious, including the fulfillment of clear clinical, biochemical, and radiographic criteria. The high reproducibility of NP-59 scintigraphic interpretation was demonstrated when 40 random cases underwent interinstitutional exchange and through interobserver evaluation at the University of Michigan. Responses of 85/126 medical centers to questionnaires revealed the high level of NP-59 safety.

Full Text

Duke Authors

Cited Authors

  • Kazerooni, EA; Sisson, JC; Shapiro, B; Gross, MD; Driedger, A; Hurwitz, GA; Mattar, AG; Petry, NA

Published Date

  • April 1990

Published In

Volume / Issue

  • 31 / 4

Start / End Page

  • 526 - 534

PubMed ID

  • 2324830

Pubmed Central ID

  • 2324830

Electronic International Standard Serial Number (EISSN)

  • 1535-5667

International Standard Serial Number (ISSN)

  • 0161-5505

Language

  • eng